Cystic echinococcosis (hydatid disease)

Expanded study digest for a new ID fellow coming from IM — deliberately fuller than usual (parasite, staging, diagnosis, procedures, and beyond-scope context are orientation scaffolding). Treatment recommendations, doses, staging, and tiers are from the WHO 2025 guideline. The amber "How practice reached here — and what's still moving" section is reviewer synthesis of newer/older evidence, each claim cited. Not a substitute for the full guideline.

◆Orientation — the parasite and how patients present

• Life cycle (dog–sheep). The adult tapeworm (up to 7 mm) lives in a definitive host (dogs/canids), shedding eggs in feces. Intermediate hosts (sheep, other livestock) — and, accidentally, humans — ingest eggs; larvae cross the gut and seed hydatid cysts in organs. Humans are a dead-end host (we don't transmit).
• Species. Almost all human CE is E. granulosus sensu stricto (G1, G3) or E. canadensis (G6, G7). Treatment does not differ by species. Distinct from alveolar echinococcosis (E. multilocularis, grows like a malignancy) — a different disease, NOT covered here.
• Presentation. Asymptomatic incubation of months to years to decades. Symptoms come from mass effect (RUQ pain, hepatomegaly, biliary obstruction) or complications — rupture (→ anaphylaxis, secondary dissemination), secondary bacterial infection, or cysto-biliary fistula. Liver is most common; lung is second (~¼ of cysts); also bone, brain, kidney, spleen, heart. lung fraction per Weber 2023, PMID 37578473
• Where. Endemic in pastoral/rural regions — South America, North Africa, Eastern/Mediterranean Europe, the Middle East, Central Asia, Russia, China; tied to sheep-raising and shepherd dogs. In non-endemic countries think of it in migrants or travelers from endemic areas with a cystic liver lesion. endemicity per guideline §1.1.1; migrant framing is reviewer orientation

◆The staging system you must know — WHO-IWGE ultrasound classification

Ultrasound stage drives everything. Active = CE1–CE3b; inactive = CE4–CE5. Clinically, CE1 and CE3a behave alike (unilocular, drainable), and CE2 and CE3b behave alike (daughter cysts / solid content — hard to clear with drug or simple aspiration).

• Wall calcification alone does NOT equal inactivity — any stage can show some calcification. Only the whole morphology stages the cyst.
• Original Gharbi (1981) US grades were re-mapped by the WHO-IWGE; the CE1–CE5 scheme is the current standard. Brunetti 2010, PMID 19931502

◆Diagnosis the fellow drives

• Imaging is primary — ultrasound (or MRI). CT is less reliable for staging (misses membranes/septa) though useful for calcification and anatomy; MRI/MRCP for biliary involvement.
• Serology complements imaging when it's inconclusive — but sensitivity/specificity are imperfect (false-negatives with lung, calcified, or CE4/CE5 cysts). No commercial antigen-detection test exists.
• Contrast enhancement argues AGAINST CE — a true hydatid cyst does not take up contrast.
• Seronegative + undetermined: confirm by microscopy of aspirate (protoscoleces/hooks), histology, PCR of cyst material, or watching for membrane detachment after ALB or puncture.
• There is no WHO diagnostic guideline yet — flagged as a research priority.

◆The toolkit — drugs and procedures

• Albendazole (ALB) — the benzimidazole backbone; cysticidal but slow. 10–15 mg/kg/day in 2 divided doses (≤400 mg BID), with a fat-rich meal (boosts absorption). Given continuously — not the 1980s cyclic "month-on/month-off." Active metabolite = albendazole sulfoxide.
• Praziquantel (PZQ) — protoscolecidal, NOT cysticidal (kills protoscoleces, doesn't kill the cyst). Adjunct only for spillage. Raises ALB-sulfoxide levels.
• PAIR (Puncture–Aspiration–Injection–Re-aspiration) — US-guided: puncture, aspirate fluid, inject a protoscolecidal agent (classically 15–20% hypertonic saline or ethanol) for 10–20 min, re-aspirate. For CE1/CE3a. Under ALB cover. agent examples are standard technique, not specified in this guideline
• S-CAT / Mo-CAT — catheter-based percutaneous evacuation that also removes the germinal/laminated layers (± daughter cysts). Mo-CAT targets the solid/daughter-cyst content of CE2/CE3b that PAIR can't clear — but exists in only a handful of expert (tier-4) centers.
• Surgery — radical (total cystectomy/pericystectomy, removes all layers incl. adventitia) vs non-radical (partial/subtotal cystectomy). Open or laparoscopic.
• Watch-and-wait — serial imaging of inactive cysts, no drug or procedure.

◆The health-tier framework (new in this guideline)

Each recommendation is tied to the infrastructure needed to deliver it safely. Where the tier isn't available, refer.

• Tier 1 Medical doctor, basic labs, ultrasound referral → ALB only.
• Tier 2 + general surgeon, anesthesia, OR, on-site US → + non-radical surgery.
• Tier 3 + laparoscopic surgeon, PAIR/S-CAT-trained physician, CT, fluoroscopy → + radical/laparoscopic surgery, PAIR, S-CAT.
• Tier 4 + thoracic surgery, interventional radiology, MRI/MRCP, advanced lab → + Mo-CAT, lung surgery.

◆Treatment recommendations — all 7 (uncomplicated cysts)

Dosing & peri-procedural rules

• ALB monotherapy: 10–15 mg/kg/day (≤400 mg BID), continuously, typically 3–6 months.
• Peri-procedural ALB: 1–7 days before, continue 1–3 months after. For large / CE1 cysts prone to ALB-related perforation, shorten pre-procedure ALB (sometimes a single dose).
• Spillage regimen: ALB ≥3 months (usually 6–12) + PZQ 40–50 mg/kg/day divided BID × 2 weeks (up to 4).
• Biliary communication (bile-stained aspirate, or contrast entering the biliary tree): do NOT inject a scolecidal agent — use S-CAT drainage without scolecidal + ALB to 6 months, or surgery/medical management.

Response & follow-up

• Lack of response = no cyst change at 3 months (no membrane detachment, size reduction, or stage change).
• Complete response is judged no earlier than 12 months after treatment ends.
• Follow-up imaging at 3–6 months, then yearly for ≥5 years after inactivation.

◆Not treated / individualized — the rest of the spectrum

• Inactive CE4/CE5 → watch-and-wait. The guideline makes no formal recommendation but endorses current practice: monitor with imaging, avoid surgery unless a complication develops (e.g., a cyst causing portal hypertension).
• Complicated liver cysts (rupture, biliary fistula, secondary infection) are out of scope → usually surgery, at an expert center.
• Extrahepatic/extrapulmonary sites, multiple cysts, mixed stages, multi-organ disease → individualized management; refer to an expert / WHO collaborating center.
• Pulmonary caveat: hepatic staging does NOT transfer to the lung, and ALB can be harmful in lung cysts (can open cysto-bronchial fistulas / precipitate complications) — hence "surgery, no ALB first." Weber/Stojkovic 2023, PMID 37578473

◆Special populations

• Pregnancy: ALB contraindicated in the first trimester; later, only if benefit > risk. Watch-and-wait is often chosen for inactive/transitional cysts. Contraception for reproductive-age women on long-term ALB. Lissandrin 2022, PMID 35405650
• ALB safety monitoring: contraindicated in cysts at risk of rupture; caution in chronic liver disease; avoid in bone-marrow depression. Monitor LFTs (hepatotoxicity) and CBC.
• Children: included in scope; laparoscopy is favored for peripheral cysts to minimize scarring.

◆Anki cards minted this run

1. First-line for small active liver cyst (CE1/CE3a <5 cm) → albendazole alone.
2. Active (CE1–CE3b) vs inactive (CE4/CE5) stages; inactive → watch-and-wait.
3. Daughter-cyst cysts (CE2/CE3b): small → ALB first; >5 cm → surgery + ALB.
4. PAIR is for CE1/CE3a and is contraindicated with biliary communication.
5. Praziquantel = protoscolecidal, not cysticidal; adjunct only for spillage.
6. Albendazole: contraindicated in 1st-trimester pregnancy and cysts at risk of rupture; monitor LFTs + CBC.
7. Lung CE ≤5 cm → surgery; do NOT give ALB before lung surgery.
8. All 7 WHO 2025 recs are conditional / very-low-certainty (2024 Cochrane: 3 RCTs).
9. ALB dosing: 10–15 mg/kg/day, ≤400 mg BID, with a fat-rich meal, continuous 3–6 mo.
10. Contrast enhancement argues against CE; no commercial antigen test.

Sources: WHO guidelines for the treatment of patients with cystic echinococcosis. Geneva: WHO; 2025 (ISBN 978-92-4-011047-2). Currency layer: Brunetti E, et al. Acta Trop 2010;114:1–16 (PMID 19931502); Kuehn R, Uchiumi LJ, Tamarozzi F. Cochrane Database Syst Rev 2024;7:CD015573 (PMID 38994714, doi:10.1002/14651858.CD015573); Lissandrin R, et al. Am J Trop Med Hyg 2018;99:375–379 (PMID 29869600); Brunetti E, Tamarozzi F. Curr Opin Infect Dis 2023;36:326–332 (PMID 37466115); Weber TF, Junghanss T, Stojković M. Curr Opin Infect Dis 2023;36:318–325 (PMID 37578473); Lissandrin R, et al. Am J Trop Med Hyg 2022;106:1684–1687 (PMID 35405650); Vuitton DA, et al. Parasite 2020;27:41 (PMID 32500855); Tamarozzi F, et al. Lancet Infect Dis 2018;18:769–778 (PMID 29793823). Trials via ClinicalTrials.gov. Literature via PubMed.